Patents by Inventor Fernando Rock

Fernando Rock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8115026
    Abstract: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.
    Type: Grant
    Filed: December 2, 2009
    Date of Patent: February 14, 2012
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Stephen J. Baker, Tsutomu Akama, Michael Richard Kevin Alley, Steven J. Benkovic, Michael DiPierro, Vincent S. Hernandez, Karin M. Hold, Isaac Kennedy, Igor Likhotvorik, Weimin Mao, Kirk R. Maples, Jacob J. Plattner, Fernando Rock, Virginia Sanders, Aaron M. Stemphoski, George Petros Yiannikouros, Siead Zegar, Yong-Kang Zhang, Huchen Zhou
  • Publication number: 20100292504
    Abstract: This invention provides, among other things, novel compounds useful for treating bacterial infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.
    Type: Application
    Filed: July 30, 2010
    Publication date: November 18, 2010
    Applicant: Anacor Pharmaceuticals, Inc.
    Inventors: Stephen J. Baker, Vincent S. Hernandez, Rashmi Sharma, James A. Nieman, Tsutomu Akama, Yong-Kang Zhang, Jacob J. Plattner, Michael Richard Kevin Alley, Rajeshwar Singh, Fernando Rock
  • Publication number: 20100267981
    Abstract: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.
    Type: Application
    Filed: December 2, 2009
    Publication date: October 21, 2010
    Applicant: Anacor Pharmaceuticals, Inc.
    Inventors: Stephen J. Baker, Tsutomu Akama, Michael Richard Kevin Alley, Steven J. Benkovic, Michael DiPierro, Vincent S. Hernandez, Karin M. Hold, Isaac Kennedy, Igor Likhotvorik, Weimin Mao, Kirk R. Maples, Jacob J. Plattner, Fernando Rock, Virginia Sanders, Aaron M. Stemphoski, George Petros Yiannikouros, Siead Zegar, Yong-Kang Zhang, Huchen Zhou
  • Patent number: 7816344
    Abstract: This invention provides, among other things, novel oxaboroles which are monosubstituted at the 3-, 6-, or 7-position, or disubstituted at the 3-/6- or 3-/7- positions, which are useful for treating bacterial infections, pharmaceutical compositions containing such oxaboroles, as well as combinations of these oxaboroles with at least one additional therapeutically effective agent.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: October 19, 2010
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Stephen J. Baker, Vincent S. Hernandez, Rashmi Sharma, James A. Nieman, Tsutomu Akama, Yong-Kang Zhang, Jacob J. Plattner, Michael Richard Kevin Alley, Rajeshwar Singh, Fernando Rock
  • Publication number: 20090227541
    Abstract: This invention provides, among other things, novel compounds useful for treating bacterial infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.
    Type: Application
    Filed: June 19, 2008
    Publication date: September 10, 2009
    Applicant: Anacor Pharmaceuticals, Inc.
    Inventors: Stephen J. Baker, Vincent S. Hernandez, Rashmi Sharma, James A. Nieman, Tsutomu Akama, Yong-Kang Zhang, Jacob J. Plattner, Michael Richard Kevin Alley, Rajeshwar Singh, Fernando Rock
  • Publication number: 20080025974
    Abstract: Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention and treatment of septic shock, inflammatory conditions, and viral infections.
    Type: Application
    Filed: August 23, 2007
    Publication date: January 31, 2008
    Inventors: Gerard Hardiman, Fernando Rock, J. Bazan, Robert Kastelein, Stephen Ho, Yong-Jun Liu
  • Publication number: 20070155699
    Abstract: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.
    Type: Application
    Filed: August 16, 2006
    Publication date: July 5, 2007
    Applicant: Anacor Pharmaceuticals
    Inventors: Stephen Baker, Tsutomu Akama, Michael Alley, Steven Benkovic, Michael DiPierro, Vincent Hernandez, Karin Hold, Isaac Kennedy, Igor Likhotvorik, Weimin Mao, Kirk Maples, Jacob Plattner, Fernando Rock, Virginia Sanders, Aaron Stemphoski, George Yiannikouros, Siead Zegar, Yong-Kang Zhang, Huchen Zhou
  • Publication number: 20050112659
    Abstract: Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention and treatment of septic shock, inflammatory conditions, and viral infections.
    Type: Application
    Filed: October 28, 2004
    Publication date: May 26, 2005
    Inventors: Gerard Hardiman, Fernando Rock, J. Bazan, Robert Kastelein, Stephen Ho, Yong-Jun Liu